Back to Authors

Piuzzi, Nicolás S.

https://orcid.org/0000-0003-3007-7538

Mayo Clinic

Cleveland Clinic

Citations 3

Experts Achieve Consensus on a Majority of Statements Regarding Platelet‐Rich Plasma Treatments for Treatment of Musculoskeletal Pathology
Hurley, Eoghan T. , Sherman, Seth L. , Stokes, Daniel J. , Shapiro, Shane A. , Mautner, Kenneth , Buford, Don , Dragoo, Jason L. , Mandelbaum, Bert R. , Zaslav, Kenneth R. , Cole, Brian J. , Hall, Mederic M. , Piuzzi, Nicolás S. , Shapiro, Shane , Mautner, Kenneth R , Rodeo, Scott A. , Frank, Rachel M

Arthroscopy | August 23, 2023 | Volume: 40 | Issue: 2 | Pages: 470

10.1016/j.arthro.2023.08.020 Get It

Purpose To establish consensus statements on platelet‐rich plasma (PRP) for the treatment of musculoskeletal pathologies. Methods A consensus process on the treatment of PRP using a modified Delphi technique was conducted. Thirty‐five orthopaedic surgeons and sports medicine physicians participated in these consensus statements on PRP. The participants were composed of representatives of the Biologic Association, representing 9 international orthopaedic and musculoskeletal professional societies invited due to their active interest in the study of orthobiologics. Consensus was defined as achieving 80% to 89% agreement, strong consensus was defined as 90% to 99% agreement, and unanimous consensus was indicated by 100% agreement with a proposed statement. Results There was consensus on 62% of statements about PRP. Conclusions (1) PRP should be classified based on platelet count, leukocyte count, red blood count, activation method, and pure‐plasma versus fibrin matrix; (2) PRP characteristics for reporting in research studies are platelet count, leukocyte count, neutrophil count, red blood cell count, total volume, the volume of injection, delivery method, and the number of injections; (3) the prognostic factors for those undergoing PRP injections are age, body mass index, severity/grade of pathology, chronicity of pathology, prior injections and response, primary diagnosis (primary vs postsurgery vs post‐trauma vs psoriatic), comorbidities, and smoking; (4) regarding age and body mass index, there is no minimum or maximum, but clinical judgment should be used at extremes of either; (5) the ideal dose of PRP is undetermined; and (6) the minimal volume required is unclear and may depend on the pathology. Level of Evidence Level V, expert opinion.
Physical Therapist Management of Total Knee Arthroplasty
Jette, Diane U., Burkett, Lynn, Langham, Bud, Logerstedt, David , Piuzzi, Nicolás S. , Poirier, Noreen M, Radach, Linda J L, Ritter, Jennifer, Tompkins, James, Zeni, Joseph , Hunter, Stephen J, Ritter, Jennifer E, Scalzitti, David A. , Stevens‐Lapsley, Jennifer E.

Physical Therapy | June 4, 2020 | Volume: 100 | Issue: 9 | Pages: 1603-1631

10.1093/ptj/pzaa099 Get It

Abstract A clinical practice guideline on total knee arthroplasty was developed by an American Physical Therapy (APTA) volunteer guideline development group that consisted of physical therapists, an orthopedic surgeon, a nurse, and a consumer. The guideline was based on systematic reviews of current scientific and clinical information and accepted approaches to management of total knee arthroplasty.
Glenohumeral Osteoarthritis: The Role for Orthobiologic Therapies
Rossi, Luciano Andrés , Piuzzi, Nicolás S. , Shapiro, Shane A. , Shapiro, Shane , Rossi, Luciano A

JBJS Reviews | February 4, 2020 | Volume: 8 | Issue: 2 | Pages: e0075-e0075

10.2106/jbjs.rvw.19.00075 Get It

» The glenohumeral (GH) joint ranks third on the list of the large joints that are most commonly affected by osteoarthritis, after the knee and the hip. » General nonsurgical modalities, including changes in daily activities, physical therapy, pharmacotherapy, and corticosteroid injections, constitute the mainstay of treatment. Most of these options, however, have shown moderate and short-term effectiveness. » Arthroplasty techniques have proven to be successful for elderly patients. Nevertheless, replacement options are not optimal for younger patients because their functional demands are higher and prostheses have a finite life span. » This has led to the search for new nonoperative treatment options to target this subgroup of patients. It has been suggested that orthobiologic therapies, including platelet-rich plasma (PRP) and cell therapies, present great promise and opportunity for the treatment of GH osteoarthritis. » Despite the promising results that have been shown by cell therapies and PRP for treating degenerative joint conditions, additional studies are needed to provide more definitive conclusions.